To discover new rheumatoid arthritis (RA) risk loci, we systematically examined 370 SNPs from 179 independent loci with P < 0.001 in a published meta-analysis of RA genomewide association studies (GWAS) of 3,393 cases and 12,462 controls 1 . We used Gene Relationships Across Implicated Loci (GRAIL) 2 , a computational method that applies statistical text mining to PubMed abstracts, to score these 179 loci for functional relationships to genes in 16 established RA disease loci 1,3-11 . We identified 22 loci with a significant degree of functional connectivity. We genotyped 22 representative SNPs in an independent set of 7,957 cases and 11,958 matched controls. Three were convincingly validated: CD2-CD58 (rs11586238, P = 1 × 10 -6 replication, P = 1 × 10 -9 overall), CD28 (rs1980422, P = 5 × 10 -6 replication, P = 1 × 10 -9 overall) and PRDM1 (rs548234, P = 1 × 10 -5 replication, P = 2 × 10 -8 overall). An additional four were replicated (P < 0.0023): TAGAP (rs394581, P = 0.0002 replication, P = 4 × 10 -7 overall), PTPRC (rs10919563, P = 0.0003 replication, P = 7 × 10 -7 overall), TRAF6-RAG1 (rs540386, P = 0.0008 replication, P = 4 × 10 -6 overall) and FCGR2A (rs12746613, P = 0.0022 replication, P = 2 × 10 -5 overall). Many of these loci are also associated to other immunologic diseases.
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammatory polyarthritis 12 . Genetic studies have now identified multiple risk alleles for autoantibody-positive RA within the MHC region, a PTPN22 missense allele, and risk alleles in 14 other loci ( Table 1) 1, [3] [4] [5] [6] [7] [8] [9] [10] [11] . Most RA risk loci contain multiple genes, and currently the causal genes within most risk loci are unknown. However, most RA risk loci contain at least one plausible biological candidate gene involved in immune regulation, and these genes suggest an important set of processes involved in RA pathogenesis. For example, risk alleles highlight genes involved in T-cell activation by antigen-presenting cells (class II MHC region, PTPN22, STAT4 and CTLA4), the NF-κB signaling pathway (CD40, TRAF1, TNFSF14 and TNFAIP3, and the recent report of REL 13 ), citrullination (PADI4), natural killer cells (CD244) and chemotaxis (CCL21).
Based on these observations, we hypothesized that as-yetundiscovered autoantibody-positive RA risk loci might also contain genes with functions similar to those of genes in known risk loci. Therefore, known RA risk loci can be used to prioritize SNPs for replication from GWAS in independent samples ( Fig. 1) , especially those SNPs with modest statistical support.
To objectively quantify the degree of functional similarity between genes within candidate loci identified from GWAS and genes within validated RA risk loci, we used a published functional genomics method, GRAIL (Gene Relationships Across Implicated Loci) 2 . GRAIL quantifies functional similarity between genes by applying established statistical text mining methods 14 to a database of 250,000 published scientific abstracts about human and model-organism genes. For each candidate locus, GRAIL identifies the gene with the greatest number of observed relationships to other genes. GRAIL estimates the statistical significance of the number of observed relationships with a null model in which relationships between genes near SNPs occur by Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk 1 3 1 4 volume 41 | number 12 | december 2009 Nature GeNetics l e t t e r s random chance. This significance score, P text , represents the output GRAIL score. GRAIL is already able to effectively identify functional interconnectivity between genes within the previously known RA loci ( Fig. 2) ; it might also be able to establish connections between these 16 loci and as-yet-undiscovered RA risk loci.
Because GRAIL might show variable performance across different phenotypes, we wanted to carefully quantify its predictive ability in RA before using it to prioritize SNPs for replication. To estimate GRAIL's ability to distinguish true RA loci from spurious associations, we examined 12 RA risk loci discovered since 2006 ( Table 1 , Supplementary Table 1 ). The current GRAIL implementation is based on PubMed abstracts published before December 2006. As these 12 risk loci were discovered since this date, they constitute a representative set to evaluate GRAIL's performance. In a 'leave-one-out' analysis, we used GRAIL to score each of these loci for functional relationships to the other 15 validated RA risk loci. A total of 10 of the 12 loci obtained GRAIL scores of P text < 0.01. This analysis suggests that at this P text threshold, GRAIL has an ~83% true positive rate (or sensitivity). To assess the false positive rate of this same P text threshold, we modeled spurious loci by sampling 10,000 random SNPs from the Affymetrix 500K array; we scored these SNPs against all 16 RA loci. Of the randomly selected SNPs, 5.4% scored P text <0.01; this corresponds to a specificity of ~95%. Assessment of true and false positive rates at different cutoffs revealed an area under the curve (or C statistic) of 0.97 ( Supplementary Fig. 1 ). We note that if a large number of candidate SNPs are screened in a study, this might still result in a large number of false positives.
Next, we attempted to identify new RA risk loci from a set of SNPs with modest evidence of association from our recent GWAS metaanalysis of 3,392 affected individuals (cases) and 12,462 controls 1 . In our original study, we genotyped SNPs with P < 10 -4 in the metaanalysis and found that 6 out of 31 SNPs replicated in our independent samples. However, many RA risk alleles have modest effects (for example, OR < 1.2) and will be missed at that significance threshold. We therefore expected that some SNPs at P < 0.001 may be risk alleles. After excluding SNPs that were known, validated RA risk loci, we identified a total of 370 SNPs from 179 independent regions that obtained P < 0.001 (Online Methods and Supplementary Note). The total number of SNPs observed at this threshold was consistent with the approximate number of SNPs expected by chance, suggesting that the majority of these SNPs represent spurious associations and should not be reproducible in an independent case-control study.
For each of the 179 candidate loci, we selected the single SNP with the strongest evidence from the GWAS meta-analysis and then scored it against the 16 validated RA risk loci with GRAIL. If all 179 SNPs were spurious, then ~10 should score P text < 0.01 based on the estimated 5.4% false positive rate. However, 22 of the 179 (12.3%) scored P text < 0.01 ( Fig. 3a, Supplementary Table 2 ). This represented a significant enrichment compared to random sets of 179 SNPs (P = 3.3 × 10 -4 by simulation). We therefore expected that of this select subset of 22 SNPs, as many as half might represent true RA risk alleles.
To identify which of these 22 SNPs represented true RA risk loci, we genotyped them in an independent validation study of 7,957 cases and 11,958 controls from 11 collections from Europe and North America (Supplementary Table 3 ). All cases met the 1987 American College of Figure 1 Using Gene Relationships Across Implicated Loci (GRAIL) to prioritize candidate RA SNPs. We selected a set of candidate SNPs to pursue in an independent genotyping experiment by starting with all SNPs that obtained P < 0.001 in an independent GWAS meta-analysis. Then, for each candidate SNP, GRAIL identified the genomic region in LD and identified overlapping genes. It then checked to see how many other loci already known to be associated with disease contained functionally related genes. SNPs representing those candidate loci with significantly related genes were forwarded for genotyping in large numbers of independent case-control samples. 
l e t t e r s
Rheumatology classification criteria 15 or were diagnosed by a board-certified rheumatologist and were seropositive for disease-specific autoantibodies (anticyclic citrullinated peptide (CCP) antibody or rheumatoid factor (RF)). All individuals were self-described as "white" and of European ancestry. We assessed association with a Cochran-Mantel-Haenszel (CMH) stratified association statistic 16 .
For each SNP, we calculated a z score, where a z > 0 indicates the same allele confers risk in both the replication and the meta-analysis samples. To interpret statistical significance, we used a Bonferroni-corrected one-tailed P value of 0.0023 (calculated as 0.05/22, z > 2.83). Additionally, we calculated the overall association P value across all samples (GWAS meta-analysis plus replication). Notably, of the 22 SNPs examined, 19 (86%) obtained z > 0 ( Fig. 3b ). If these SNPs represented spurious associations, then only about half should have z > 0; the probability of such a positive skew in the number of SNPs with z > 0 by chance alone is P skew = 0.0005, suggesting a high likelihood of a large number of true RA risk loci within this set of 22 SNPs.
Of the 22 SNPs selected by GRAIL, 13 obtained nominal levels of association to RA at P < 0.05 (corresponding to z > 1.65), whereas no more than 2 might be expected by chance alone. More compellingly, seven SNPs achieved a Bonferroni-corrected level of significance in replication (P < 0.0023, z > 2.83).
When we aggregated both GWAS meta-analysis and replication genotype data ( Table 2 , Supplementary Table 4 ), we observed the strongest evidence of association to RA at rs11586238 on 1p13.1 near the CD2 and CD58 genes (P = 1.4 × 10 -6 replication, P = 1.0 × 10 -9 overall), at rs1980422 on 2q33.2 near CD28 (P = 4.7 × 10 -6 replication, P = 1.3 × 10 -9 overall) and at rs548234 on 6q21 near PRDM1 (P = 1.2 × 10 -5 replication, P = 2.1 × 10 -8 overall). Based 
Figure 2 GRAIL identified interconnectivity among genes in RA loci. The known RA-associated SNPs are along the outer ring; the internal ring represents the genes near each SNP (as listed in table 1); each box in the internal ring represents an individual gene. We illustrate the literature-based functional connectivity between these genes with lines drawn between them-the redder and thicker the lines are, the stronger the connectivity between the genes is. RA SNPs implicate a small number of highly connected genes-those genes are indicated by labeled boxes. we calculated a one-sided CMH z-score statistic from our two-staged replication data. A z score of 0 corresponds to a P = 0.5, a z score of 1.65 to P = 0.05, and a z score of 2.83 to P = 0.0023. For a random collection of unassociated SNPs, the histogram should approximate a normal distribution (dotted line). l e t t e r s on conservative estimates of genome-wide significance (P = 5 × 10 -8 ), these SNPs represent confirmed RA risk alleles. Four additional loci replicated; however, in aggregate analysis of GWAS meta-analysis and replication genotype data, no loci exceeded a conservative estimate of significance. We observed evidence of association at rs394581 on 6q25.3 near TAGAP (P = 1.5 × 10 -4 replication, P = 3.8 × 10 -7 overall), rs10919563 on 1q31.3 within a PTPRC intron (P = 2.6 × 10 -4 replication, P = 6.7 × 10 -7 overall), rs540386 on 11p12 within a TRAF6 intron (P = 8.3 × 10 -4 replication, P = 3.9 × 10 -6 overall) and rs12746613 on 1q23.3 near FCGR2A (P = 2.2 × 10 -3 replication, P = 1.5 × 10 -5 overall). These SNP associations likely represent true RA loci, but additional genotyping will be necessary for definitive confirmation.
Notably, many of the SNPs picked by GRAIL that validated in independent genotyping were not those with strongest evidence of association in the initial GWAS meta-analysis ( Fig. 3a) . That is, prioritization based purely on meta-analysis P values might have missed many of these associations. For example, rs12746613 (FCGR2A) was ranked 163 of 179 and rs540386 (RAG1-TRAF6) was ranked 110. Of the five SNPs that we genotyped with the most significant GRAIL P text scores, three replicated and one showed nominal evidence of association; only rs2614394 (IRAK4) showed no evidence of association.
Many of these seven alleles further implicate genomic regions already associated with autoimmune diseases ( Table 3) . At this point, none of these RA risk alleles correspond perfectly to any previously established autoimmune allele, but in some cases, fine mapping of the region in multiple diseases could clarify the relationships between the alleles. The rs12746613 SNP in FCGR2A is 13 kb away from a missense SNP in FCGR2A that has been associated with systemic lupus erythematosus 17, 18 ; these two SNPs are in the same LD block (r 2 = 0.19, D′ = 1.0). The rs394581 SNP is located in the 5′ untranslated region of TAGAP and is 17 kb away from a SNP associated with celiac disease and with type 1 diabetes 19, 20 ; these two SNPs are in partial LD (r 2 = 0.32, D′ = 0.73). The rs10919563 SNP in PTPRC is 35 kb away from a rare (~1% allele frequency) nonsynonymous SNP that alters splicing of PTPRC 21 ; there have been inconsistent reports that the latter allele is associated with multiple sclerosis [22] [23] [24] . We also note that the rs7234029, a PTPN2 intronic SNP, is 41 kb away from a SNP associated with both type 1 diabetes and celiac disease 20 ; these two alleles are in the same LD block (r 2 = 0.14, D′ = 1.0). The rs548234 SNP is The first six columns list SNP characteristics. The next four columns list GWA meta-analysis results including allele frequencies, a two-tailed P value for SNP association and an odds ratio (OR) with respect to the minor allele. The next four columns list similar results for replication genotyping; significance is reported based on stratified one-tailed CMH statistic. The next three columns summarize joint (overall) analysis results; significance is reported based on stratified two-tailed CMH statistic across all 14 patient collections (3 from the meta-analysis and 11 from the replication study). The final column lists the Breslow-Day Test for heterogeneity of odds ratios across all 14 collections. a These SNPs are close to other loci already associated to autoimmune disease. l e t t e r s located 10 kb downstream from the PRDM1 transcript and is 133 kb away from a SNP previously associated with Crohn's disease 25 . The rs11586238 SNP is 50 kb upstream of the CD2 start site but is also near multiple other key immunological genes including CD58 and IGSF2. This SNP is also 159 kb away from a multiple sclerosis-associated SNP within a CD58 intron 26, 27 . The rs1980422 SNP is located about 10 kb away from the 3′ untranslated region of CD28 and is 129 kb away from a known RA and type 1 diabetes risk allele in the CTLA4 region (rs3087243) 11 . There is minimal LD between these two SNPs (r 2 = 0.04, D′ = 0.40); conditional analysis confirmed that these two SNPs independently confer RA risk (see Supplementary Table 5 ).
These SNP associations continue to clarify critical biological processes involved in RA pathogenesis, including T-cell activation, NF-κB signaling and B-cell activation and differentiation. The CD2 protein is a co-stimulatory molecule on the surface of natural killer cells and T-cells; signaling through CD2 is mediated by its binding of PTPRC directly 28 . SNP association to CD28 contributes additional evidence of the role of T-cell activation in disease pathogenesis. TRAF6 is involved in downstream NF-κB activation; it binds CD40 directly and is a key component of B-cell activation 29 . Our study has also implicated new processes represented by PRDM1 (also known as BLIMP-1), a transcription factor that regulates terminal differentiation of B-cells into immunoglobulin secreting plasma cells 30 . Functional studies and resequencing will be required to confirm that these genes are indeed the truly causal genes for RA pathogenesis.
We examined all seven replicated RA SNPs along with known RA risk alleles for epistatic interactions (Supplementary Note) . Despite the functional relationships between these genes, we found no evidence of significant interactions.
Population stratification could result in spurious associations. However, we were careful for each collection to use either epidemiologically matched samples or ancestry-informative markers to match cases and controls. We further note that our 7 replicated SNP associations showed consistent effects across all 14 collections without evidence of heterogeneity (P > 0.05 by Breslow-Day test of heterogeneity, Table 2 ).
In this study, we demonstrated the utility of functional information to prioritize SNPs for replication. We did not predefine pathways but rather used GRAIL to look for genes that had relationships to other validated RA genes. We note that GRAIL is limited in its ability to identify disease genes in entirely new pathways (that is, pathways not suggested by the 16 previously known RA risk loci). Arguably, it is those disease genes that could point to truly new pathogenic mechanisms. Additionally, successful application of GRAIL is contingent on the scientific literature's comprehensive description of relevant gene relationships. The general application of GRAIL to other diseases will depend critically on the completeness of the validated loci list and the documentation about relevant processes in the literature. Despite these limitations, our study has identified at least three previously unknown RA risk loci and has showed strong evidence for additional risk loci.
MeThodS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. Seven of the 22 SNPs tested are near loci already associated with autoimmune diseases. The first three columns list the SNPs, cytogenetic location and the likely candidate gene. The next three columns list the published SNP, the attributed gene and the disease associations. The final three columns list the physical distance and measures of LD.
For PTPRC, the published SNP is rare and LD cannot be accurately assessed.
oNLINe MeThodS
Evaluating GRAIL for its ability to identify RA loci. GRAIL is a method that leverages statistical text-mining principles to assess whether putative disease loci harbor genes with functional relationships to genes in other associated disease loci 2 . Two genes are considered similar if the words used to describe them in PubMed abstracts suggest similar functionality. The implementation of GRAIL used here leverages a text database of 250,000 abstracts published before December 2006.
To test the ability of GRAIL to distinguish RA risk loci from spurious associations, we defined a set of true positive loci that were discovered since December 2006; these loci would not be described in the GRAIL text database. We also approximated a set of spurious associations by randomly selecting 10,000 SNPs from the Affymetrix 500K genotyping array. We tested both SNP sets for relationships to known RA-associated loci with GRAIL. Validated SNPs were tested against the other 15 independent loci; spurious SNPs were tested against all 16 loci. The sensitivity was defined as the proportion of true positive associations that GRAIL assigned a P text < 0.01 significance score; the specificity was defined as the proportion of spurious associations that GRAIL assigned a P text > 0.01 significance score.
Selecting nominally associated SNPs for follow-up. To identify SNPs for follow-up, we examined the results of a recently published meta-analysis of three GWAS studies ( Supplementary Table 3 ) 1 . We examined 336,721 SNPs outside the MHC region that passed strict quality control criteria. We identified those SNPs that were nominally associated with RA (P < 0.001). We grouped SNPs into independent loci; two SNPs were placed in the same locus if there was evidence of LD (r 2 > 0.1 in CEU HapMap). We removed all loci that overlapped with validated RA risk regions ( Table 1) . We also removed loci with P < 10 -4 that were genotyped in most available patient collections and had failed to validate in a previous study 1 . From the remaining set of independent loci, we selected the single SNP that showed the greatest evidence of association in the published meta-analysis.
Testing SNPs with GRAIL. We tested 179 candidate SNPs using GRAIL for relationships to genes within the 16 independent loci known to be associated with RA. SNPs that obtained compelling GRAIL scores (P text < 0.01) were selected for follow-up investigation. To assess the degree of enrichment among high scoring SNPs, we sampled 100,000 random sets of 179 SNPs and tested these SNP sets with GRAIL. We calculated the proportion of sets with as many or more GRAIL hits to calculate a permutation-based P value. We note that the version of GRAIL that we used is a previous implementation that differs slightly from the published implementation 2 -results are not substantially affected when those for the same experiment done with the current version of GRAIL (Supplementary Fig. 2) . Subject collections. The collections including the study participants with RA and matched controls are described in detail in Supplementary Table 3 and in the Supplementary Note. Each collection consisted only of individuals that were self-described as being "white" and of European descent, and all cases either met the 1987 American College of Rheumatology classification criteria or were diagnosed with RA by board-certified rheumatologists. Informed consent was obtained from each participant, and the Institutional Review Board at each collecting site approved the study.
All cases were autoantibody positive (CCP and/or RF). For most of the collections, matched control samples were collected along with case samples as part of the same study. For some of the collections, where control samples were unavailable, we matched these case collections to shared controls. We used a total of 11 separate case-control collections for replication genotyping: (i) CCP-positive cases from the Brigham Rheumatoid Arthritis Sequential Study (BRASS) 31 and controls from three separate studies on multiple sclerosis 32 13 and controls recruited from the same site along with additional controls taken from a disease study of lung cancer 34 ; (iii) CCP-positive cases and controls from Halifax and Toronto (CANADA-II) 13 ; (iv) CCP-positive cases from Sweden and epidemiologically matched controls (EIRA-II) 35 ; (v) CCP-positive Dutch cases and controls collected from the greater Amsterdam region (GENRA) 36, 37 ; (vi) North American RF-positive cases and controls matched on gender, age and grandparental country of origin from the Genomics Collaborative Initiative (GCI) 4 ; (vii) CCP-or RF-positive Dutch cases and controls from Leiden University Medical Center (LUMC) 38, 39 ; (viii) CCPpositive cases drawn from North American clinics and controls from the New York Cancer Project (together this collection is called NARAC-II) 13, 35 ; (ix) CCP-positive cases drawn from North American clinics (NARAC-III) 13 and publicly available controls taken from a Parkinson's study 40 and study 66 and 67 of the Illumina Genotype Control Database; (x) CCP-or RF-positive cases identified by chart review from the Nurses Health Study (NHS) and matched controls based on age, gender, menopausal status and hormone use 41 ; and (xi) CCP-or RF-positive cases recruited at multiple sites in the United Kingdom by the United Kingdom Rheumatoid Arthritis Genetics (UKRAG) collaboration 6 . We used available SNP data from this and previous studies to identify genetically identical samples from the same country; we assumed these represented duplicated individuals and removed them.
Genotyping.
A detailed description of the genotyping done is provided in the Supplementary Note. All GWAS meta-analysis genotyping was previously described. We genotyped replication samples at the Broad Institute (Cambridge, Massachusetts, USA) using a single Sequenom iPlex Pool (for the EIRA-II and GENRA collections) and Affymetrix 6.0 (BRASS), the US National Institutes of Health using a single Sequenom iPlex Pool (NARAC-II), the Analytic Genetics Technology Centre in Toronto using a single Sequenom iPlex Pool (CANADA-II), the Epidemiology Unit at the University of Manchester using a single Sequenom iPlex Pool (UKRAG), Celera (Alameda, California, USA) using kinetic PCR 42 (GCI and LUMC), at the Nurses Health Study in Boston using the BioTrove multiplex SNP genotyping assay (NHS), at the Feinstein Institute (Manhasset, New York) using the Illumina 317K array (NARAC-III); and at Illumina (San Diego, California) using the Illumina 370K array (CANADA). For NARAC-III we additionally obtained publicly available shared controls genotyped on a similar platform from two separate studies. In the cases where whole genome data were available, we either extracted data for the 22 SNPs (BRASS) or used imputation to estimate genotypes for them (CANADA and NARAC-III).
For each collection, we applied stringent quality control criteria. We required that each SNP pass the following criteria for each collection separately: (i) genotype missing rate < 10%, (ii) minor allele frequency > 1% and (iii) Hardy-Weinberg equilibrium with P > 10 -3 . We then excluded individuals with data missing for >10% of SNPs passing quality control.
Population stratification. For each replication collection, we corrected for possible population stratification by either using only epidemiologically matched samples when cases and controls were drawn from the same population, or matching at least one control for each case based on ancestry-informative markers (see Supplementary Note for details). Because the cases in the NHS, GCI, LUMC, EIRA-II, CANADA-II, UKRAG and GENRA collections were well matched to controls, we did not pursue further strategies to correct for population stratification. For the BRASS, NARAC-II, CANADA and NARAC-III collections, we matched cases and controls with ancestry-informative markers and placed them each into a single stratum. For the BRASS cases and shared controls, GWAS data on Affymetrix 6.0 (unpublished data) was available; we used 681,637 SNPs passing strict quality control as ancestry-informative markers. For NARAC-II cases and NYCP shared controls, cases and controls were matched using genotype data on 760 ancestry-informative markers. For the NARAC-III cases and shared controls, we used available Illumina 317K GWAS data for 269,771 SNPs passing stringent quality control criteria. For the CANADA cases and controls, we used available Illumina 317K GWAS data for 269,771 SNPs passing stringent quality control criteria. For each case-control collection, we used these SNPs to define the top ten principal components and to remove genetically distinct outliers (sigma threshold, 6 with 5 iterations) with the software program EIGENSTRAT 43 . We eliminated vectors that correlated with known structural variants on chromosomes 8 and 17, showed minimal variation, or did not stratify cases and controls. After mapping cases and controls in the space of eigenvectors, we matched cases to controls that were nearest in euclidean distance as described elsewhere 1 .
